Comparison between Ambey Laboratories IPO and Visaman Global Sales IPO.
Ambey Laboratories IPO is a SME Fixed Price IPO proposed to list at NSE SME while Visaman Global Sales IPO is a SME Fixed Price proposed to list at NSE SME.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fast Track Finsec Pvt.Ltd. | Shreni Shares Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Nikunj Stock Brokers Ltd. | Shreni Shares Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Ambey Laboratories IPO is up to ₹42.43 Cr whereas the issue size of the Visaman Global Sales IPO is up to ₹15.22 Cr. The final issue price of Ambey Laboratories IPO is ₹68.00 per share and of Visaman Global Sales IPO is ₹43.00 per share.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | |
| Issue Price (Upper) | ₹68.00 per share | |
| Issue Price (Final) | ₹68.00 per share | ₹43.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 3000 shares |
| Fresh Issue Size | 59,28,000 shares | 35,40,000 shares |
| Fresh Issue Size (Amount) | up to ₹40.31 Cr | up to ₹15.22 Cr |
| OFS Issue Size | 3,12,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹2.12 Cr | up to ₹0.00 Cr |
| Issue Size Total | 62,40,000 shares | 35,40,000 shares |
| Issue Size Total (Amount) | up to ₹42.43 Cr | up to ₹15.22 Cr |
Ambey Laboratories IPO opens on Jul 04, 2024, while Visaman Global Sales IPO opens on Jun 24, 2024. The closing date of Ambey Laboratories IPO and Visaman Global Sales IPO is Jul 08, 2024, and Jun 26, 2024, respectively.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |
|---|---|---|
| Anchor Bid Date | Jul 03, 2024 | |
| Issue Open | Jul 04, 2024 | Jun 24, 2024 |
| Issue Close | Jul 08, 2024 | Jun 26, 2024 |
| Basis Of Allotment (Tentative) | Jul 09, 2024 | Jun 27, 2024 |
| Initiation of Refunds (Tentative) | Jul 10, 2024 | Jun 28, 2024 |
| Credit of Share (Tentative) | Jul 10, 2024 | Jun 28, 2024 |
| Listing date (Tentative) | Jul 11, 2024 | Jul 01, 2024 |
| Anchor Lockin End date 1 | Aug 08, 2024 | |
| Anchor Lockin End date 2 | Oct 07, 2024 |
Ambey Laboratories IPO P/E ratio is 27.81, as compared to Visaman Global Sales IPO P/E ratio of 38.25.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Ambey Laboratories Limited Financial Information (Restated)
| Visaman Global Sales Limited Financial Information (Restated)Visaman Global Sales Limited's revenue increased by 16.04% and profit after tax (PAT) rose by 19.72% between the financial year ending with March 31, 2023 and March 31, 2022.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 94.97 | 100.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69.90 | 72.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 27.81 | 38.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹171.64 Cr. | ₹59.39 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 20.80% | 9.28% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 13.14% | 8.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.58 | 5.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.44 | ₹1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 20.80% | 9.28% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Ambey Laboratories IPO Retail Individual Investors (RII) are offered 21,84,000 shares while in Visaman Global Sales IPO retail investors are offered 21,84,000 shares. Qualified Institutional Buyers (QIB) are offered 12,48,000 shares in Ambey Laboratories IPO and in Visaman Global Sales IPO.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |
|---|---|---|
| Anchor Investor Reserveration | 18,72,000 shares | |
| Market Maker Reserveration | 3,30,000 shares | 1,92,000 shares |
| QIB | 12,48,000 shares | |
| NII | 9,36,000 shares | 17,70,000 shares |
| RII | 21,84,000 shares | 17,70,000 shares |
| Employee | ||
| Others | ||
| Total | 62,40,000 shares | 35,40,000 shares |
Ambey Laboratories IPO subscribed 173.18x in total, whereas Visaman Global Sales IPO subscribed 42.20x.
| Ambey Laboratories IPO | Visaman Global Sales IPO | |
|---|---|---|
| QIB (times) | 61.90x | |
| NII (times) | 324.22x | 28.12x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 195.06x | 51.54x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 173.18x | 42.20x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
